You are currently viewing a new version of our website. To view the old version click .

Advances in Respiratory Medicine

Advances in Respiratory Medicine (ARM) is an international, peer-reviewed, open access journal on respiratory medicine, covering allergology, oncology, immunology and infectious diseases of the respiratory system, and is published bimonthly online.
It is the official journal of the Polish Respiratory Society (PtChP).
Indexed in PubMed | Quartile Ranking JCR - Q2 (Respiratory System)

All Articles (1,615)

Cryptic Circulation and Co-Infections of Endemic Human Coronaviruses During the First Years of the COVID-19 Pandemic in Brazil

  • Ana Karolina Mendes Moreno,
  • Rajiv Gandhi Gopalsamy and
  • Lucas Alves da Mota Santana
  • + 8 authors

During the COVID-19 pandemic, the global focus on SARS-CoV-2 overshadowed the epidemiology of other respiratory pathogens. This study aimed to characterize the circulation of endemic human coronaviruses (HCoVs) in Brazil. We retrospectively analyzed results from 22,472 PCR tests for HCoVs (from 5183 patients) and 601,278 tests for SARS-CoV-2 (from 475,856 patients) between November 2019 and June 2021. HCoVs were detected in 160 patients (3.09%), with HCoV-NL63 as the most frequent species. HCoV circulation was intermittent, with positivity peaks up to 4% but also periods of up to six months with an absence of detections in 2020, contrasting with the sustained high positivity of SARS-CoV-2 (22.37%). Co-infections were frequent: 26.25% of HCoV-positive patients were co-infected with at least one other respiratory pathogen, most commonly Rhinovirus/Enterovirus, and cases involving up to five pathogens were observed, seven patients had co-infections between HCoVs and SARS-CoV-2. These findings reveal the persistent, often cryptic, circulation of HCoVs during the pandemic and highlight their role as key components in complex multi-pathogen infections. This underscores the critical importance of implementing comprehensive molecular diagnostic panels in routine respiratory surveillance to ensure accurate etiology, guide appropriate clinical management, and fully assess the public health burden of non-SARS-CoV-2 coronaviruses.

5 December 2025

Flowchart showing the number of patients tested and those who tested positive for the four endemic human coronaviruses (HCoVs) and SARS-CoV-2 between November 2019 and June 2021. Data were obtained from PCR screening tests conducted in five Brazilian hospitals and made available by the COVID-19 Data Sharing/BR repository.

Background: Obstructive sleep apnea (OSA) is recognized as a systemic disorder associated with several comorbidities, including renal dysfunction, which may improve with continuous positive airway pressure (C-PAP) therapy. Sleep fragmentation and nocturnal hypoxia characteristic of OSA have been implicated in carcinogenesis, particularly affecting hypoxia-sensitive urinary tract tissues. This study aimed to assess the prevalence of different cancer types among patients with concurrent OSA and malignancy and to characterize the clinical profiles of those with urinary tract cancer. Methods: We retrospectively analyzed 50 patients with both OSA and cancer from the Vercelli Hospital Registry. Cancer diagnoses were collected at the time of OSA diagnosis, prior to C-PAP initiation. Results: Among the cohort (70% males) of OSA-cancer patients, urinary tract cancers were the most frequent (34%), followed by breast (14%), colorectal (12%), lung (10%), laryngeal and skin (8%), intracranial (6%), hematologic and parotid (4%), and other cancers (2%); 10% had multiple cancer sites. Patients with urinary tract cancer were mainly male (88%, p = 0.0043) and displayed better respiratory indices, frequent hypertension, and higher C-PAP adherence. Conclusions: These findings suggest a possible link between OSA-related hypoxia and carcinogenesis in urinary tract tissues and support increased clinical surveillance and further research to determine potential protective effects of C-PAP therapy.

27 November 2025

Distribution of cancer types among OSA patients according to subgroup. Different neoplasms (e.g., lung, thyroid, parotid, laryngeal, intracranial, stomach) are exclusively present in the X0 group (non-urinary tract cancer) or in the combined cohort, with no representation in X1 (urinary tract cancer), suggesting distinct clinical distributions. Skin, breast, and colorectal cancers show overlapping presence in both groups, indicating shared clinical features. The X1 group displays a higher relative proportion of skin cancer, possibly reflecting specific pathophysiological or demographic patterns. Data are expressed as percentage of patients (%). Abbreviations: X0 = non-urinary tract cancer; X1 = urinary tract cancer.

Chronic obstructive pulmonary disease (COPD) is a major health burden in India with limited real-world data on triple inhaler therapy. This prospective, open-label, multi-center, single-arm, phase 4 study (October 2023–August 2024) assessed the effectiveness and safety of glycopyrronium/formoterol fumarate/budesonide (GFB) triple therapy, administered as metered-dose inhaler (MDI) or dry-powder inhaler (DPI), in Indian COPD patients. Symptomatic patients aged ≥40 years with minimum one exacerbation in the past year and receiving dual or monotherapy were included. GFB was delivered as MDI or DPI based on physician and patient preference. Primary outcomes were changes from baseline in trough forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and modified medical research council (mMRC) score over 24 weeks, with assessment of exacerbations, hospitalizations, rescue medication use, and safety. In 184 patients (70.65% male, mean age 53.7 years), GFB significantly improved FEV1, FVC, and mMRC scores. Eleven mild exacerbations were reported without hospitalization; 17.39% used rescue salbutamol largely in the first 4 weeks. GFB was well tolerated, with mild-to-moderate adverse events in 14.67%, and outcomes were comparable between MDI and DPI. Our findings support GFB as safe and effective treatment in real-world COPD management.

25 November 2025

Improvements in (a) trough FEV1 (mL), (b) trough FVC (mL), (c) trough FEV1%, and (d) mMRC score over 24 weeks of therapy with GFB (glycopyrronium/formoterol fumarate/budesonide) triple therapy. Note: * p < 0.05 compared to baseline. FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; mMRC = modified medical research council.
  • Feature Paper
  • Article
  • Open Access

Introduction: Minimally invasive video-assisted thoracic surgery (VATS) for lung cancer has become a widely used approach. However, postoperative pulmonary complications (PCs) such as pneumonia, atelectasis, and lung fistula remain significant challenges, particularly in older adult patients with multiple comorbidities. The 6-minute walk test (6MWT) has been suggested as a predictor of postoperative outcomes in various surgical settings, but its relationship with postoperative complications following VATS lobectomy for lung cancer has not been thoroughly explored. The aim of this study was to determine if preoperative 6MWD predicted the occurrence of 30-day PCs among patients undergoing VATS lobectomy for non-small-cell lung cancer. Methods: This retrospective study examined 66 patients who underwent VATS lobectomy for lung cancer. Participants were categorized into two groups: those with postoperative pulmonary complications (n = 11) and those without (n = 55). The research period was from January to September 2022. The preoperative 6MWT distance, along with other clinical and demographic factors, was assessed to determine its predictive value for postoperative complications. Multivariate logistic regression analysis was performed to identify significant predictors. Results: The study found that preoperative 6MWT ≤ 450 m was a significant predictor of postoperative pulmonary complications (odds ratio: 5.674, 95% CI: 1.206–26.684, p = 0.028). Conclusions: The preoperative 6MWT distance is a useful predictor of postoperative pulmonary complications in patients undergoing VATS lobectomy for lung cancer. Patients with a 6MWT ≤ 450 m may be at higher risk for complications such as pneumonia, atelectasis, and lung fistula. Incorporating preoperative 6MWT as a risk stratification tool could help guide clinical decisions and rehabilitation efforts to improve postoperative outcomes in this patient population.

24 November 2025

(A) Receiver operating characteristic (ROC) curve of the 6-minute walk test (6MWT) for postoperative overall complications. Data-driven optimal cut-off (Youden index) at 450 m with sensitivity 0.694 and specificity 0.588; area under the curve (AUC) 0.636. (B) ROC curve of the 6-minute walk test (6MWT) for postoperative pulmonary-related complications. Data-driven optimal cut-off (Youden index) at 450 m with sensitivity 0.673 and specificity 0.818; AUC 0.703.

News & Conferences

Issues

Open for Submission

Editor's Choice

Reprints of Collections

Acute Respiratory Distress Syndrome (ARDS)
Reprint

Acute Respiratory Distress Syndrome (ARDS)

Personalized Therapies and Beyond
Editors: Denise Battaglini, Paolo Pelosi

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Adv. Respir. Med. - ISSN 2543-6031